AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22192670 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (ex vivo)
Number of subjects: 303
Study 22192670 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 303
Study 20658483 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus gasseri A5 (n = 49)
Number of subjects: 105
Study 20658483 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 56)
Number of subjects: 105
Study 17187610 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole + Amoxicillin-Clarithromycin (OAC)
Number of subjects: 46
Study 17187610 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-Clarithromycin (AC)
Number of subjects: 46
Study 17187610 — intervention group
Group type: EXPERIMENTAL
Intervention: Both OAC and AC regimens
Number of subjects: 46
Study 15203997 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% cream
Number of subjects: 173
Study 15203997 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin 0.05% emollient cream
Number of subjects: 173
Study 11599659 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 150 IU/kg s.c. three times weekly (t.i.w.)
Number of subjects: 36
Study 11599659 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa 40,000 IU s.c. once weekly (q.w.)
Number of subjects: 36
Study 11599659 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (t.i.w. and q.w.)
Number of subjects: 36
Study 9836024 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (0.25 mg/kg)
Number of subjects: 11
Study 9836024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 8137476 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐Fluorouracil (5‐FU) at 330 mg/m2 per week, Adriamycin (ADR) at 20 mg/m2 every 4 weeks, and mitomycin C (MMC) at 2.7 mg/m2 every 2 weeks
Number of subjects: 56
Study 8137476 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐Fluorouracil (5‐FU) at 330 mg/m2 per week and epirubicin (EPIR) at 20 mg/m2 every 2 weeks
Number of subjects: 56
Study 2912533 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide and lorazepam
Number of subjects: 64
Study 2912533 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide alone
Number of subjects: 64
Study 1202613 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimipramine (50 mg tablets, perorally, 3 hours before test)
Number of subjects: 10
Study 1202613 — intervention group
Group type: COMPARATOR
Intervention: Histalog (1 mg per kg body weight, intramuscular injection)
Number of subjects: 10
Study 29453769 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing (genotyping)
Number of subjects: 2255
Study 29453769 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV33
Number of subjects: 2255
Study 29453769 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16
Number of subjects: 2255
Study 29453769 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV35
Number of subjects: 2255
Study 29453769 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (HPV types 33, 16, 35)
Number of subjects: 2255
Study 29453769 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A or B (HPV types 31, 52, 18, 59, 58)
Number of subjects: 2255
Study 29453769 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A or B or C (HPV types 39, 51, 56, 45, 68)
Number of subjects: 2255
Study 29453769 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 2255
Study 29453769 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B
Number of subjects: 2255
Study 29453769 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C
Number of subjects: 2255
Study 28963278 — intervention group
Group type: EXPERIMENTAL
Intervention: GoActive intervention
Number of subjects: 2400
Study 26645928 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care + video messaging
Number of subjects: 912
Study 26645928 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 912
Study 24284080 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech and images (group 2)
Number of subjects: 42
Study 24284080 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech, images, and image annotation (group 3)
Number of subjects: 42
Study 24284080 — intervention group
Group type: COMPARATOR
Intervention: Speech only (group 1)
Number of subjects: 42
Study 21116186 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (specific details not provided)
Number of subjects: 603
Study 18607309 — intervention group
Group type: COMPARATOR
Intervention: No ARV use
Number of subjects: 93
Study 18607309 — intervention group
Group type: COMPARATOR
Intervention: Unprotected sexual intercourse
Number of subjects: 93
Study 18607309 — intervention group
Group type: COMPARATOR
Intervention: Viral load >1000 copies/mL
Number of subjects: 93
Study 18607309 — intervention group
Group type: COMPARATOR
Intervention: Median viral loads
Number of subjects: 93
Study 18607309 — intervention group
Group type: COMPARATOR
Intervention: ARV use
Number of subjects: 93
Study 17167159 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chih (TCC) for 20 minutes
Number of subjects: 32
Study 17167159 — intervention group
Group type: COMPARATOR
Intervention: Passive rest (control group)
Number of subjects: 32
Study 17167159 — intervention group
Group type: COMPARATOR
Intervention: Slow-moving physical activity (videotape-guided stretching for 20 minutes)
Number of subjects: 32
Study 12585099 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripterygiitotorum (T II) plus prednisone
Number of subjects: 68
Study 12585099 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 68
Study 10612483 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix (10 mg daily subcutaneous injections for five days and 60 mg depot)
Number of subjects: 10
Study 10612483 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix (10 mg daily intramuscular injections for five days and placebo depot)
Number of subjects: 10
Study 10612483 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily and depot injections)
Number of subjects: 10
Study 10612483 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix (pooled data from groups C + C and C + P)
Number of subjects: 10
Study 7742423 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone/pyrimethamine (200/75 mg once weekly)
Number of subjects: 501
Study 7742423 — intervention group
Group type: COMPARATOR
Intervention: Aerosolized pentamidine (300 mg once every 4 weeks)
Number of subjects: 501
Study 7742423 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone/pyrimethamine
Number of subjects: 501
Study 2184183 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography (two-dimensional and Doppler)
Number of subjects: 70
Study 6998284 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 22
Study 6998284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 6998284 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon and Placebo
Number of subjects: 22
Study 31634023 — intervention group
Group type: EXPERIMENTAL
Intervention: Wixela Inhub (FP/salmeterol 100/50 μg)
Number of subjects: 1127
Study 31634023 — intervention group
Group type: EXPERIMENTAL
Intervention: Advair Diskus (FP/salmeterol 100/50 μg)
Number of subjects: 1127
Study 29351117 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with comorbid anxiety disorders
Number of subjects: 178
Study 29351117 — intervention group
Group type: COMPARATOR
Intervention: Subjects without comorbid anxiety disorders
Number of subjects: 178
Study 28267249 — intervention group
Group type: COMPARATOR
Intervention: ASA 81 mg once-daily
Number of subjects: 68
Study 28267249 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA 162 mg twice-daily
Number of subjects: 68
Study 28267249 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA 325 mg once-daily
Number of subjects: 68
Study 28267249 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA 162 mg twice-daily or 81 mg four times daily (pooled data)
Number of subjects: 68
Study 28267249 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA 325 mg once-daily (pooled data)
Number of subjects: 68
Study 26528651 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage-based smoking cessation services
Number of subjects: 223
Study 26528651 — intervention group
Group type: COMPARATOR
Intervention: Usual aftercare
Number of subjects: 223
Study 23924680 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole
Number of subjects: 252
Study 23924680 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 252
Study 20880870 — intervention group
Group type: EXPERIMENTAL
Intervention: Cylinder oxygen provided at 6 l/min intranasally during activities provoking breathlessness
Number of subjects: 143
Study 20880870 — intervention group
Group type: COMPARATOR
Intervention: Cylinder air provided at 6 l/min intranasally during activities provoking breathlessness
Number of subjects: 143
Study 18465129 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F fluoride PET-CT
Number of subjects: 38
Study 18465129 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F FCH PET-CT
Number of subjects: 38
Study 16796502 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconference telepsychiatry (VCTP) treatment
Number of subjects: 140
Study 16796502 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face conventional (F2FC) treatment
Number of subjects: 140
Study 16796502 — intervention group
Group type: EXPERIMENTAL
Intervention: Both VCTP and F2FC treatments
Number of subjects: 140
Study 12752071 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine progestogens
Number of subjects: 0
Study 12752071 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifibrinolytic agents (tranexamic acid)
Number of subjects: 0
Study 12752071 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory agents (mefenamic acid)
Number of subjects: 0
Study 12752071 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial destructive techniques
Number of subjects: 0
Study 12752071 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibroid embolization
Number of subjects: 0
Study 10739510 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-keto-desogestrel (1.5, 3, or 6 microg daily)
Number of subjects: 203
Study 10739510 — intervention group
Group type: COMPARATOR
Intervention: Control (0 microg of 3-keto-desogestrel)
Number of subjects: 203
Study 9209517 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intraluminal brachytherapy (IBT) - moderate-dose group (16-40 Gy; n = 96)
Number of subjects: 115
Study 9209517 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intraluminal brachytherapy (IBT) - high-dose group (40-80 Gy; n = 19)
Number of subjects: 115
Study 9209517 — intervention group
Group type: COMPARATOR
Intervention: Control group (no radiation prior to radical surgery; n = 115)
Number of subjects: 115
Study 8130430 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous swim-up/swim-down procedure
Number of subjects: 0
Study 8130430 — intervention group
Group type: COMPARATOR
Intervention: Discontinuous Percoll gradient centrifugation
Number of subjects: 0
Study 8130430 — intervention group
Group type: COMPARATOR
Intervention: Swim-up method
Number of subjects: 0
Study 8130430 — intervention group
Group type: EXPERIMENTAL
Intervention: Swim-down sperm
Number of subjects: 0
Study 8130430 — intervention group
Group type: EXPERIMENTAL
Intervention: Swim-up/swim-down procedure
Number of subjects: 0
Study 3312501 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol 200-800 mg/day
Number of subjects: 29
Study 3312501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 29845573 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic Conditioning (IC)
Number of subjects: 207
Study 29845573 — intervention group
Group type: COMPARATOR
Intervention: No Ischemic Conditioning (NIC)
Number of subjects: 207
Study 27556593 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 61
Study 27556593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 24618385 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG-F 9 mg/kg
Number of subjects: 0
Study 24618385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22409587 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES) for bifurcation lesions
Number of subjects: 814
Study 22409587 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 814
Study 20868907 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (10 mg)
Number of subjects: 91
Study 20868907 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (10 mg)
Number of subjects: 91
Study 20868907 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (5 mg) / Midazolam (5 mg)
Number of subjects: 91
Study 18942250 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ketamine 40 mg
Number of subjects: 0
Study 18942250 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine 2 mg
Number of subjects: 0
Study 15672012 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 50 mg
Number of subjects: 346
Study 15672012 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 100 mg
Number of subjects: 346
Study 15672012 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg
Number of subjects: 346
Study 15672012 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 400 mg
Number of subjects: 346
Study 15672012 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 600 mg
Number of subjects: 346
Study 15672012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 346
Study 11982665 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity resistance training (HI)
Number of subjects: 30
Study 11982665 — intervention group
Group type: COMPARATOR
Intervention: Low-velocity resistance training (LO)
Number of subjects: 30
Study 10326343 — intervention group
Group type: EXPERIMENTAL
Intervention: Acemannan hydrogel wound dressing
Number of subjects: 30
Study 10326343 — intervention group
Group type: COMPARATOR
Intervention: Moist saline gauze dressing
Number of subjects: 30
Study 7813413 — intervention group
Group type: EXPERIMENTAL
Intervention: 4,5,6,7‐tetrahydroisoxazolo[5,4‐c]pyridin‐3‐ol (THIP)
Number of subjects: 9
Study 7813413 — intervention group
Group type: EXPERIMENTAL
Intervention: THIP
Number of subjects: 9
Study 2782650 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow injection (250 sec) of 10 mg hypobaric tetracaine with epinephrine
Number of subjects: 20
Study 2782650 — intervention group
Group type: COMPARATOR
Intervention: Fast injection (10 sec) of 10 mg hypobaric tetracaine with epinephrine
Number of subjects: 20
Study 180195 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic inactivation with neutral red and light
Number of subjects: 96
Study 180195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 6939841 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal brush
Number of subjects: 19
Study 6939841 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpicks
Number of subjects: 19
Study 6939841 — intervention group
Group type: COMPARATOR
Intervention: Toothbrush alone
Number of subjects: 19
Study 6939841 — intervention group
Group type: COMPARATOR
Intervention: Toothbrush combined with toothpicks
Number of subjects: 19
Study 6939841 — intervention group
Group type: COMPARATOR
Intervention: Toothbrush combined with proximal brush
Number of subjects: 19
Study 30982743 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resistance starch, low-protein flour (50 g daily at lunch and dinner for 12 weeks)
Number of subjects: 75
Study 30982743 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resistance starch, low-protein flour
Number of subjects: 75
Study 30982743 — intervention group
Group type: COMPARATOR
Intervention: Control group (protein-restriction diet with common staple)
Number of subjects: 75
Study 28003374 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss
Number of subjects: 164
Study 28003374 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 164
Study 28003374 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance
Number of subjects: 164
Study 25402418 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous peripheral blood SCT (APBSCT)
Number of subjects: 292
Study 25402418 — intervention group
Group type: COMPARATOR
Intervention: Autologous BMT (ABMT)
Number of subjects: 292
Study 25402418 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher numbers of mobilized CD34+ cells (both groups)
Number of subjects: 292
Study 25029619 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 79
Study 25029619 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 79
Study 22703639 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training for physiotherapists (8 hours of training including handouts, workbooks, video examples, role-play, and discussion)
Number of subjects: 292
Study 22703639 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (physiotherapists did not receive communication skills training)
Number of subjects: 292
Study 19478337 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOPA (isocaloric beverage with added protein and vitamins)
Number of subjects: 12
Study 19478337 — intervention group
Group type: COMPARATOR
Intervention: CHO (isocaloric carbohydrate drink)
Number of subjects: 12
Study 17225918 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat milk products enriched with plant stanol esters (2 g of stanols per day for 5 weeks)
Number of subjects: 199
Study 17225918 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 199
Study 15051639 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm-control strategy
Number of subjects: 4059
Study 15051639 — intervention group
Group type: COMPARATOR
Intervention: Rate-control strategy
Number of subjects: 4059
Study 12549790 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted-double phototherapy (DP) using daylight fluorescent lamps
Number of subjects: 51
Study 12549790 — intervention group
Group type: COMPARATOR
Intervention: Conventional phototherapy (CP)
Number of subjects: 51
Study 9715861 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg PO BID for 12 weeks
Number of subjects: 81
Study 9715861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 7847212 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolized group
Number of subjects: 0
Study 7847212 — intervention group
Group type: COMPARATOR
Intervention: Nonembolized group
Number of subjects: 0
Study 2569394 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of somatostatin in 2 ml saline (Group I)
Number of subjects: 25
Study 2569394 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of somatostatin in 10 ml saline (Group II)
Number of subjects: 25
Study 2569394 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin in a loading dose of 250 micrograms followed by an infusion of 125 micrograms h-1 (Group III)
Number of subjects: 25
Study 2569394 — intervention group
Group type: COMPARATOR
Intervention: Control of ventilation studies in Group I
Number of subjects: 25
Study 776314 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam (10 mg)
Number of subjects: 20
Study 776314 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine (25 mg)
Number of subjects: 20
Study 776314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30694977 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-protein diet (50% carbohydrate, 20% fat, 30% protein)
Number of subjects: 10
Study 30694977 — intervention group
Group type: EXPERIMENTAL
Intervention: Control diet (64% carbohydrate, 20% fat, 16% protein)
Number of subjects: 10
Study 30694977 — intervention group
Group type: COMPARATOR
Intervention: Overfeeding+inactivity (35% excess of basal energy requirements)
Number of subjects: 10
Study 28154006 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG without surgical ventricular reconstruction (n=934)
Number of subjects: 1411
Study 28154006 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG with surgical ventricular reconstruction (n=477)
Number of subjects: 1411
Study 28154006 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall CABG group (n=1411)
Number of subjects: 1411
Study 28154006 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable analysis
Number of subjects: 1411
Study 26426861 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 mg/kg IV THC
Number of subjects: 40
Study 26426861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23784379 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral risk‐reducing mastectomy (CRRM)
Number of subjects: 105
Study 23784379 — intervention group
Group type: COMPARATOR
Intervention: Non-CRRM (control group)
Number of subjects: 105
Study 23784379 — intervention group
Group type: EXPERIMENTAL
Intervention: CRRM (after matching for oophorectomy, gene, grade and stage)
Number of subjects: 105
Study 19997859 — intervention group
Group type: EXPERIMENTAL
Intervention: KetacFil (KF)
Number of subjects: 35
Study 19997859 — intervention group
Group type: EXPERIMENTAL
Intervention: PhotacFil (PF)
Number of subjects: 35
Study 19997859 — intervention group
Group type: EXPERIMENTAL
Intervention: Herculite XRV (HX)
Number of subjects: 35
Study 20017916 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy drink (Meltdown RTD); 140 ml administered in two 70 ml doses, separated by 30 min.
Number of subjects: 10
Study 20017916 — intervention group
Group type: COMPARATOR
Intervention: Placebo; 140 ml administered in two 70 ml doses, separated by 30 min.
Number of subjects: 10
Study 17550598 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 10 mg/kg/day for 7 days followed by 5 mg/kg/day for the duration of the study (up to 6 weeks)
Number of subjects: 43
Study 17550598 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 43
Study 17550598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 15581126 — intervention group
Group type: EXPERIMENTAL
Intervention: Own-race (Caucasian) faces
Number of subjects: 52
Study 15581126 — intervention group
Group type: COMPARATOR
Intervention: Other-race (Chinese) faces
Number of subjects: 52